Search clinical trials for: PD-L1 t-haNK cells

Total 16660 results

China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

Recurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant Tumors

China
Regeneron Pharmaceuticals

Terminated

Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

Advanced PD-L1 Positive Malignancies

United States
University Medical Center Groningen

Active, not recruiting

MPDL3280A-imaging-IST-UMCG

Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression

Netherlands
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11)

PD-L1-selected Solid Tumors

Korea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
Zhongnan Hospital

Recruiting

Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Baodong Qin

Unknown

Effect of Chemotherapy on PD-L1 in NSCLC

Chemotherapy | Immunotherapy | PD-L1

China
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
Consorzio Oncotech

Completed

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study (ARIES)

Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer

Italy
Inge Marie Svane

Completed

Dual Vaccine Trial in Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia

Denmark
Yonsei University
Merck KGaA, Darmstadt, Germany

Active, not recruiting

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

PD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation Tumor

Korea, Republic of
Lars Møller Pedersen

Completed

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

Follicular Lymphoma

Denmark
Tatarstan Cancer Center

Unknown

Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer

Hereditary Breast Cancer

Russian Federation
Hoffmann-La Roche

Completed

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell

United Kingdom, Czechia, Germany, Poland, Spain, Switzerland
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Solid Tumor | Metastatic Cancer | Locally Advanced Solid Tumor

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
Baodong Qin

Unknown

Effect of Chemotherapy on TMB in NSCLC

Chemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 Inhibitor

China
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
Shanghai Zhongshan Hospital

Recruiting

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Cholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4

China
Medical University of Vienna

Unknown

CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients

Non Small Cell Lung Cancer

Austria
Sichuan University

Not yet recruiting

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Peking Union Medical College Hospital

Recruiting

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Hepatocellular Carcinoma

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
University Hospital, Angers

Completed

Exosomes Implication in PD1-PD-L1 Activation in OSAS (ExoSAS)

Cancer | Sleep Apnea Syndromes, Obstructive

France
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
Sichuan University

Recruiting

Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Pleural Effusion, Malignant | Peritoneal Carcinoma Metastatic

China
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
The Second Hospital of Nanjing Medical University

Unknown

Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

Primary Hepatocellular Carcinoma
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Italy, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Herlev and Gentofte Hospital
University of Copenhagen

Completed

A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma

Basal Cell Carcinoma

Denmark
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NSCLC | Advanced Solid Tumor

United States, China
Lene Meldgaard Knudsen
IO Biotech

Terminated

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Denmark
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Naestved Hospital

Recruiting

Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.

Non-small Cell Lung Cancer | Malignant Pleural Effusion

Denmark
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

HIV Infections | HIV-1-infection | PD-L1 Gene Mutation

China
Sarah Goldberg
Mirati Therapeutics Inc.

Terminated

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States
Maastricht Radiation Oncology

Completed

Immune Profiling After HDR in Local Relapsed Prostate Cancer (PRIMUS)

Prostate Cancer | PD-L1

Netherlands
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Cervical Cancer | Advanced Solid Tumor

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Hodgkin's Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Canada, United States, Brazil, Czechia, France, Italy, Poland, Russian Federation, South Africa, Turkey, Ukraine
Merck Sharp & Dohme LLC

Completed

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Primary Mediastinal B-Cell Lymphoma
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Second Affiliated Hospital of Soochow University

Not yet recruiting

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Carcinoma | Solid Tumor

China
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency

United States
Lene Meldgaard Knudsen

Completed

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Multiple Myeloma

Denmark

Search clinical trials for: PD-L1 t-haNK cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations